In an open-label, nonrandomised, uncontrolled, add-on trial, D-amphetamine (5–10 mg p.o. id) was added to L-DOPA (3-4 grams, administered without an AADC inhibitor) in 9 PD patients. The gene discussed is DDC; the disease is Parkinson disease.